ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Amy Reyes

Amy Reyes

Amy Reyes is editor of Rheumatology Network.  She is an experienced journalist and science writer who has worked as a staff writer for Mayo Clinic, the University of Michigan and Duke University Medical Center, where she specialized in covering advances in basic and clinical science in a multitude of disciplines.

Posts by Author

(©TimMasters/Shutterstock.com)

The FDA has nixed Eli Lilly's and Inctye's application for baricitinib in its current form asking for additional safety and clinical data.

(Systemic Lupus Erythematosus  ©farland80/Shutterstock.com)

Researchers suggest rheumatologists screen systemic lupus erythematosus patients for stroke risk — during the first visit.

(©BillionPhotos/Shutterstock.com)

Researchers are suggesting the adoption of triple therapy as a first-line treatment after RA patients fail methotrexate monotherapy.

Pain (©UEUAphoto/Shutterstock.com)

Kinesiophobia, or the fear of movement, may keep knee osteoarthritis patients from physical therapy and by consequence, recovery.

Chiropractic care. (©AlbinaGlisic/Shutterstock.com)

Despite clinical evidence, patients are seeking chiropractic care for back pain. This study shows there may be some merit in the practice.

Apps (©Chinnapong/Shutterstock.com)

Not all mobile apps are the same and it’s important to understand the function and quality of mobile apps for monitoring disease activity, researchers write in a review of the leading apps for RA.

Apps (©YmgermanShutterstock.com)

In this slideshow, we highlight the best of RA mobile apps that are designed to track disease activity. The list, a total of 19 apps, is based on a scientific review that was published in February.

(Gastrointestinal tract. ©Tefi/Shutterstock.com)

Inflammatory bowel disease is associated with arthritis. Research suggests there could be a genetic component or the connection could be associated with an inflamed gut. Learn more here.

(Crohn's disease ©JuanGaertner/Shutterstock.com)

The gold standard for treating Crohn's disease and ulcerative colitis may lie in anti-TNF and anti-integrins therapy, researchers report this week.

Clinical Trial (©GustavoFrazao/Shutterstock.com)

A British study finds that rituximab is "neither clinically or cost-effective" in a study of patients with primary Sjogren’s syndrome who were being treated for fatigue and oral dryness.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.